Adocia S.A. (ADOIF)
Adocia S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, FR. The stock last traded at $8.87, up 0.00% on the session, giving a market capitalisation of $103.7M. On trailing twelve-month figures it carries a trailing P/E of -4.23, a net margin of -1124.8%. Its beta of 0.72 implies it has historically moved less than the broad market.
Adocia S.A., a biotechnology firm founded in Lyon, France, in 2005, operates at the clinical stage, focusing its research and development efforts on optimizing existing therapeutic proteins and peptides for the management of diabetes and various other metabolic conditions. The company's core innovation lies in its proprietary BioChaperone technological platform, specifically engineered to enhance the effectiveness and performance of therapeutic proteins. Adocia's product pipeline currently in clinical trials features several advanced insulin formulations. These include BioChaperone Lispro U100 and U200, which offer ultra-rapid action derived from rapid insulin lispro. Other notable candidates are BioChaperone Combo, a combination of both long-acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, which pairs prandial insulin with pramlintide; BioChaperone Glucagon, an aqueous human glucagon formulation for treating low blood sugar; and M1Pram, a product based on a metabolite of insulin glargine and pramlintide. In addition to its clinical assets, Adocia boasts a strong preclinical pipeline. This includes bi-hormonal treatments such as BioChaperone AsPram, which combines rapid insulin aspart with pramlintide, and BioChaperone Glargine Liraglutidea, a fixed-dose combination of insulin glargine with a GLP-1 receptor analogue. The company is also exploring multihormonal solutions for obesity, including BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a triple therapy comprising pramlintide, glucagon, and exenatide. Globally, Adocia has established a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. This collaboration aims to develop and bring to market BioChaperone Lispro and BioChaperone Combo throughout China, as well as in other regions across Asia and the Middle East.
Adocia S.A. is most often compared with the following Healthcare names: